Analysts believe that Gilead Sciences can expect another good year because of its robust pipeline of new drugs and its HIV treatments. FDA approval this year of two drug candidates -- inhaled antibiotic aztreonam lysine for the treatment of cystic fibrosis and HIV drug Viread for the treatment of chronic hepatitis B in adults -- are expected to boost the biopharmaceutical firm's profits.

Related Summaries